tiprankstipranks
Trending News
More News >
10x Genomics Inc (TXG)
NASDAQ:TXG
US Market

10x Genomics (TXG) Stock Forecast & Price Target

Compare
1,043 Followers
See the Price Targets and Ratings of:

TXG Analyst Ratings

Moderate Buy
12Ratings
6 Buy
6 Hold
0 Sell
Based on 12 analysts giving stock ratings to
10x
Genomics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TXG Stock 12 Month Forecast

Average Price Target

$15.73
▲(97.61% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $15.73 with a high forecast of $26.00 and a low forecast of $12.00. The average price target represents a 97.61% change from the last price of $7.96.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","46":"$46","16.75":"$16.75","26.5":"$26.5","36.25":"$36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,16.75,26.5,36.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.67,10.003076923076923,11.336153846153845,12.669230769230769,14.002307692307692,15.335384615384616,16.66846153846154,18.00153846153846,19.334615384615383,20.667692307692306,22.00076923076923,23.333846153846153,24.666923076923077,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.67,9.213076923076922,9.756153846153847,10.29923076923077,10.842307692307692,11.385384615384616,11.928461538461539,12.471538461538461,13.014615384615386,13.557692307692308,14.100769230769231,14.643846153846155,15.186923076923078,{"y":15.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.67,8.926153846153847,9.182307692307692,9.438461538461539,9.694615384615386,9.95076923076923,10.206923076923077,10.463076923076922,10.71923076923077,10.975384615384616,11.231538461538461,11.487692307692308,11.743846153846153,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.56,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.05,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.42,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.59,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$26.00Average Price Target$15.73Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$18$15
Hold
88.44%
Upside
Reiterated
02/12/25
Balanced Outlook Amid Revenue Growth and Market Risks: Hold Rating for 10x GenomicsWe believe further NIH-related downside remains (assuming the total budget is cut and indirect rate is also cut), and believe incorporating a bigger impact into the guide now (perhaps even another -1%) with the stock already down could have helped reduce investor uncertainty. That said, the initial guidance impact seems logical.
Jefferies
$19
Buy
138.69%
Upside
Reiterated
02/12/25
Positive Outlook for 10x Genomics Amid Strong Financials and Growth ProspectsWe see little middle ground, as bulls argue conservatism after tough few years and newer CFO set up for beats, while bears see NIH downside, competitive dynamics and little valuation support.
Goldman Sachs
$16$14
Sell
75.88%
Upside
Reiterated
10/30/24
10X Genomics (TXG) PT Lowered to $14 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on 10X Genomics (NASDAQ: TXG) to $14.00 (from $16.00) while maintaining a Sell rating.
Deutsche Bank
$25
Hold
214.07%
Upside
Reiterated
08/09/24
10x Genomics: A Cautious Hold Amidst Revised Forecasts and Organizational Changes
Wolfe Research
Hold
Downgraded
06/27/24
10x Genomics (TXG) Receives a New Rating from a Top Analyst
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$18$15
Hold
88.44%
Upside
Reiterated
02/12/25
Balanced Outlook Amid Revenue Growth and Market Risks: Hold Rating for 10x GenomicsWe believe further NIH-related downside remains (assuming the total budget is cut and indirect rate is also cut), and believe incorporating a bigger impact into the guide now (perhaps even another -1%) with the stock already down could have helped reduce investor uncertainty. That said, the initial guidance impact seems logical.
Jefferies
$19
Buy
138.69%
Upside
Reiterated
02/12/25
Positive Outlook for 10x Genomics Amid Strong Financials and Growth ProspectsWe see little middle ground, as bulls argue conservatism after tough few years and newer CFO set up for beats, while bears see NIH downside, competitive dynamics and little valuation support.
Goldman Sachs
$16$14
Sell
75.88%
Upside
Reiterated
10/30/24
10X Genomics (TXG) PT Lowered to $14 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on 10X Genomics (NASDAQ: TXG) to $14.00 (from $16.00) while maintaining a Sell rating.
Deutsche Bank
$25
Hold
214.07%
Upside
Reiterated
08/09/24
10x Genomics: A Cautious Hold Amidst Revised Forecasts and Organizational Changes
Wolfe Research
Hold
Downgraded
06/27/24
10x Genomics (TXG) Receives a New Rating from a Top Analyst
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 10x Genomics

Which Analyst Should I Follow If I Want to Buy TXG and Sell After:
1 Month
xxx
Success Rate
9/19 ratings generated profit
47%
Average Return
-2.76%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.37% of your transactions generating a profit, with an average return of -2.76% per trade.
3 Months
xxx
Success Rate
8/19 ratings generated profit
42%
Average Return
-6.45%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -6.45% per trade.
1 Year
Tejas SavantMorgan Stanley
Success Rate
6/16 ratings generated profit
38%
Average Return
-23.08%
reiterated a buy rating 2 months ago
Copying Tejas Savant's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -23.08% per trade.
2 Years
xxx
Success Rate
2/20 ratings generated profit
10%
Average Return
-42.89%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 10.00% of your transactions generating a profit, with an average return of -42.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TXG Analyst Recommendation Trends

Rating
Nov 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
6
6
6
6
6
Buy
9
10
5
5
3
Hold
8
11
8
8
6
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
24
28
19
19
15
In the current month, TXG has received 9 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. TXG average Analyst price target in the past 3 months is 15.73.
Each month's total comprises the sum of three months' worth of ratings.

TXG Financial Forecast

TXG Earnings Forecast

Next quarter’s earnings estimate for TXG is -$0.47 with a range of -$0.65 to -$0.31. The previous quarter’s EPS was -$0.40. TXG beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.67% of the time in the same period. In the last calendar year TXG has Outperformed its overall industry.
Next quarter’s earnings estimate for TXG is -$0.47 with a range of -$0.65 to -$0.31. The previous quarter’s EPS was -$0.40. TXG beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.67% of the time in the same period. In the last calendar year TXG has Outperformed its overall industry.

TXG Sales Forecast

Next quarter’s sales forecast for TXG is $133.13M with a range of $126.91M to $144.02M. The previous quarter’s sales results were $165.02M. TXG beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.08% of the time in the same period. In the last calendar year TXG has Outperformed its overall industry.
Next quarter’s sales forecast for TXG is $133.13M with a range of $126.91M to $144.02M. The previous quarter’s sales results were $165.02M. TXG beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.08% of the time in the same period. In the last calendar year TXG has Outperformed its overall industry.

TXG Stock Forecast FAQ

What is TXG’s average 12-month price target, according to analysts?
Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is 15.73.
    What is TXG’s upside potential, based on the analysts’ average price target?
    10x Genomics Inc has 97.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TXG a Buy, Sell or Hold?
          10x Genomics Inc has a consensus rating of Moderate Buy which is based on 6 buy ratings, 6 hold ratings and 0 sell ratings.
            What is 10x Genomics Inc’s price target?
            The average price target for 10x Genomics Inc is 15.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $26.00 ,the lowest forecast is $12.00. The average price target represents 97.61% Increase from the current price of $7.96.
              What do analysts say about 10x Genomics Inc?
              10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of TXG?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis